Plain-English translation of NCT06232044 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether works better when combined with two other drugs—one experimental and one already approved—for people with multiple myeloma that has returned or stopped responding to previous treatment. Multiple myeloma is a cancer of blood cells, and this study wants to see if this three-drug combination can help patients live longer without their disease getting worse. You would be randomly assigned to receive either the three-drug combination or a two-drug combination to help researchers figure out which works best.
Multiple myeloma is a serious blood cancer that often comes back or stops responding to treatment, leaving patients with limited options. Researchers believe that this medication may work better when combined with other drugs, and this trial is designed to test whether adding the experimental drug improves survival and slows disease progression compared to the two-drug approach.
In Phase I of the study, you would take an oral medication on specific days each cycle, receive an intravenous injection on day 1, and take another oral medication on eight different days—with cycles repeating every 56 days. In Phase II, you would be randomly assigned to either the three-drug or two-drug regimen and follow a similar schedule. Throughout the trial, you would have regular blood tests, imaging scans (CT, MRI, or PET), heart function tests, and bone marrow biopsies to monitor how the treatment is working and check for side effects.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
United States